The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy.
X. Guo
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose
V. Möbus
No relevant relationships to disclose
K. Schwedler
No relevant relationships to disclose
P. A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - AstraZeneca; Novartis; Pfizer
J. Barinoff
No relevant relationships to disclose
F. Holms
No relevant relationships to disclose
C. Thomssen
Honoraria - Bristol-Myers Squibb; Sanofi
Research Funding - Bristol-Myers Squibb; Sanofi
Other Remuneration - Sanofi
D. M. Zahm
No relevant relationships to disclose
R. Kreienberg
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - Amgen; Cephalon; GlaxoSmithKline
M. Hauschild
No relevant relationships to disclose
H. Eidtmann
No relevant relationships to disclose
S. Tauchert
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
G. Von Minckwitz
No relevant relationships to disclose